CLDX Celldex Therapeutics, Inc.
Price Chart
Executive Summary
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU and SD, showing that retreatment leads to rapid and high rates of complete response, supporting the potential for intermittent, real-world treatment. The data reinforce the drug's durable efficacy and favorable safety profile, with 62% (ColdU) and 60% (SD) achieving complete response upon retreatment. A global Phase 3 trial is ongoing.
Actionable Insight
Investors should monitor enrollment progress in the Phase 3 EMBARQ trial and upcoming interim or topline results, which could serve as major catalysts. The retreatment data de-risk development by supporting flexible dosing, potentially improving compliance and commercial adoption.
Key Facts
- Barzolvolimab retreatment achieved 62% complete response in ColdU and 60% in SD at Week 20 of the OLE, consistent with initial treatment efficacy.
- Among patients who achieved complete response initially, 82% (ColdU) and 86% (SD) achieved it again upon retreatment.
- Rapid improvement in urticaria control and symptom thresholds observed upon retreatment.
- Barzolvolimab targets mast cells via KIT receptor inhibition, a novel mechanism for chronic inducible urticarias.
- Global Phase 3 trial (EMBARQ-ColdU and SD, NCT07266402) is enrolling, initiated in late 2025.
Financial Impact
High potential commercial value; addresses an underserved market with no approved therapies beyond antihistamines. Phase 3 advancement increases probability of regulatory approval and future revenue generation.
Risk Factors
- Phase 3 trial may not replicate Phase 2 results.
- Regulatory approval not guaranteed despite promising data.
- Competition could emerge if other mast cell or biologic therapies advance in urticaria.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246936 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 7, 2026
4w ago
|
8-K
| $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $29.60 (−12.86%) |
|
May 7, 2026
4w ago
|
Press Release
| $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $29.60 (−12.86%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $29.60 (−5.64%) |
|
Apr 2, 2026
9w ago
|
Press Release
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $29.60 (−4.70%) |
|
Apr 1, 2026
9w ago
|
424B5
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $29.60 (−4.70%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $29.60 (−4.70%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $30.30 $33.66 | ▲ +11.09% | ▼ −1.65% | $29.60 (−2.31%) |
|
Mar 1, 2026
14w ago
|
Press Release
| $30.00 $29.48 | ▼ −1.73% | ▲ +6.20% | $29.60 (−1.33%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $30.00 $29.48 | ▼ −1.73% | ▲ +6.20% | $29.60 (−1.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access